BRPI1008023B8 - Forma de dosagem sólida - Google Patents

Forma de dosagem sólida

Info

Publication number
BRPI1008023B8
BRPI1008023B8 BRPI1008023A BRPI1008023A BRPI1008023B8 BR PI1008023 B8 BRPI1008023 B8 BR PI1008023B8 BR PI1008023 A BRPI1008023 A BR PI1008023A BR PI1008023 A BRPI1008023 A BR PI1008023A BR PI1008023 B8 BRPI1008023 B8 BR PI1008023B8
Authority
BR
Brazil
Prior art keywords
solid dosage
dosage form
formulations
bardoxolone
particles
Prior art date
Application number
BRPI1008023A
Other languages
English (en)
Inventor
Zhang Jiang
J Meyer Colin
Original Assignee
Reata Pharmaceuticals Inc
Reata Pharmaceuticals Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42335073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI1008023(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Reata Pharmaceuticals Inc, Reata Pharmaceuticals Holdings Llc filed Critical Reata Pharmaceuticals Inc
Publication of BRPI1008023A2 publication Critical patent/BRPI1008023A2/pt
Publication of BRPI1008023B1 publication Critical patent/BRPI1008023B1/pt
Publication of BRPI1008023B8 publication Critical patent/BRPI1008023B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
    • C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Forma de Dosagem Sólida. Formulações farmacêuticas exibem um Cmax desejavelmente baixo, dentre outras propriedades, que contêm partículas de bardoxolona metil amorfa, seja em forma pura ou na forma de uma dispersão sólida, misturada com partículas de um agente de ligação hidrofílico. Essas formulações possuem a vantagem de biodisponibilidade oral mais alta, relativo para formulações com base na forma cristalina de bardoxolona metil.
BRPI1008023A 2009-02-13 2010-02-12 Forma de dosagem sólida BRPI1008023B8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15260809P 2009-02-13 2009-02-13
PCT/US2010/024127 WO2010093944A2 (en) 2009-02-13 2010-02-12 Delayed release, oral dosage compositions that contain amorphous cddo-me

Publications (3)

Publication Number Publication Date
BRPI1008023A2 BRPI1008023A2 (pt) 2016-03-15
BRPI1008023B1 BRPI1008023B1 (pt) 2019-12-31
BRPI1008023B8 true BRPI1008023B8 (pt) 2023-04-11

Family

ID=42335073

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI1008023A BRPI1008023B8 (pt) 2009-02-13 2010-02-12 Forma de dosagem sólida

Country Status (30)

Country Link
US (2) US8747901B2 (pt)
EP (2) EP2395979B1 (pt)
JP (1) JP5775464B2 (pt)
KR (2) KR20140016441A (pt)
CN (2) CN102387789A (pt)
AU (1) AU2010213594B2 (pt)
BR (1) BRPI1008023B8 (pt)
CA (1) CA2752048C (pt)
CO (1) CO6361904A2 (pt)
CY (2) CY1119595T1 (pt)
DK (2) DK3254675T3 (pt)
EA (1) EA023652B1 (pt)
ES (2) ES2646816T3 (pt)
HK (1) HK1220130A1 (pt)
HR (2) HRP20171639T1 (pt)
HU (2) HUE044005T2 (pt)
IL (1) IL214258A (pt)
LT (2) LT3254675T (pt)
MX (1) MX2011008344A (pt)
MY (1) MY173715A (pt)
NO (1) NO2395979T3 (pt)
NZ (1) NZ594488A (pt)
PL (2) PL3254675T3 (pt)
PT (2) PT2395979T (pt)
SG (1) SG173601A1 (pt)
SI (2) SI3254675T1 (pt)
SM (2) SMT201900432T1 (pt)
TR (1) TR201909743T4 (pt)
WO (1) WO2010093944A2 (pt)
ZA (1) ZA201105630B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
HUE043175T2 (hu) 2008-01-11 2019-08-28 Reata Pharmaceuticals Inc Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
MX339476B (es) 2008-04-18 2016-05-27 Reata Pharmaceuticals Inc Compuestos que incluyen un nucleo farmaceutico antiinflamatorio y sus metodos de uso.
CN104250280A (zh) 2008-04-18 2014-12-31 里亚塔医药公司 抗氧化剂炎症调节剂:c-17同系化齐墩果酸衍生物
ES2703274T3 (es) 2008-04-18 2019-03-07 Reata Pharmaceuticals Inc Moduladores de la inflamación antioxidantes: derivados del ácido oleanólico con modificaciones amino y otras en C-17
KR101713140B1 (ko) 2008-04-18 2017-03-08 리타 파마슈티컬스 잉크. Ｃ-환에서 포화된 산화방지성 염증 조절제 올레아놀산 유도체
EP2309860B1 (en) 2008-07-22 2014-01-08 Trustees of Dartmouth College Monocyclic cyanoenones and methods of use thereof
PL3254675T3 (pl) 2009-02-13 2019-09-30 Reata Pharmaceuticals, Inc. Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me
SMT202000086T1 (it) 2010-04-12 2020-03-13 Reata Pharmaceuticals Inc Bardoxolone metile per il trattamento dell'obesità
HRP20171859T1 (hr) 2010-12-17 2018-01-26 Reata Pharmaceuticals, Inc. Pirazolil i pirimidinil triciklički enoni kao antioksidacijski modulatori upale
CA2829618C (en) 2011-03-11 2019-07-09 Reata Pharmaceuticals, Inc. C4-monomethyl triterpenoid derivatives and methods of use thereof
CN103156861B (zh) * 2011-12-08 2015-11-25 陈丽梅 齐敦果酸衍生物及其可药用盐在治疗糖尿病眼病中的应用
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
US9504679B2 (en) 2011-12-19 2016-11-29 Bjoern Colin Kahrs Pharmaceutical compositions comprising glitazones and Nrf2 activators
DK3444261T3 (da) 2012-04-27 2021-03-08 Reata Pharmaceuticals Inc 2,2-difluorpropionamidderivat af bardoxolonmethyl, farmaceutiske sammensætninger og polymorfer deraf til anvendelse ved behandling af visse lidelser
US8981144B2 (en) 2012-05-08 2015-03-17 Trustees Of Dartmouth College Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof
US8921419B2 (en) 2012-05-08 2014-12-30 Trustees Of Dartmouth College Triterpenoids and compositions containing the same
US9556222B2 (en) 2012-06-15 2017-01-31 Reata Pharmaceuticals, Inc. A-ring epoxidized triterpenoid-based anti-inflammation modulators and methods of use thereof
US9512094B2 (en) 2012-09-10 2016-12-06 Reata Pharmaceuticals, Inc. C17-heteroaryl derivatives of oleanolic acid and methods of use thereof
US9278912B2 (en) 2012-09-10 2016-03-08 Reata Pharmaceuticals, Inc. C13-hydroxy derivatives of oleanolic acid and methods of use thereof
PL2892912T3 (pl) 2012-09-10 2019-10-31 Reata Pharmaceuticals Inc C17-alkanodiylowe i alkenodiylowe pochodne kwasu oleanolowego i sposoby ich zastosowania
TWI649330B (zh) 2013-04-24 2019-02-01 艾伯維有限公司 甲基巴多索龍之２，２－二氟丙醯胺衍生物、其多晶形及其使用方法
NZ774222A (en) 2013-08-23 2023-01-27 Reata Pharmaceuticals Holdings Llc Methods of treating and preventing endothelial dysfunction using bardoxolone methyl or analogs thereof
WO2016070063A1 (en) 2014-10-31 2016-05-06 The Regents Of The University Of California Compositions and methods for treating hiv-associated cognitive dysfunction
US11059792B2 (en) 2015-02-12 2021-07-13 Reata Pharmaceuticals, Inc. Imidazolyl tricyclic enones as antioxidant inflammation modulators
EA201890767A1 (ru) 2015-09-23 2019-09-30 Рита Фармасьютикалз, Инк. C4-модифицированные производные олеаноловой кислоты для ингибирования il-17 и других применений
AU2017356955B2 (en) 2016-11-08 2023-11-09 Reata Pharmaceuticals Holdings, LLC Methods of treating Alport syndrome using bardoxolone methyl or analogs thereof
TWI831738B (zh) 2016-12-16 2024-02-11 美商瑞塔醫藥有限責任公司 用於抑制ＲＯＲγ及其他用途的嘧啶三環烯酮衍生物
WO2019014412A1 (en) 2017-07-13 2019-01-17 Pliva Hrvatska D.O.O. NOVEL CRYSTALLINE POLYMORPHIC FORMS OF METHYL BARDOXOLONE
JP7244536B2 (ja) 2018-04-06 2023-03-22 キャプシュゲル・ベルジウム・エヌ・ヴィ メタクリル酸メチル－メタクリル酸コポリマーからなる低アスペクト比の粒子のための噴霧乾燥方法
CN112654610B (zh) 2018-06-15 2024-12-24 里亚塔医药公司 用于抑制IL-17和RORγ的吡唑和咪唑化合物
EP3810141A1 (en) 2018-06-20 2021-04-28 Reata Pharmaceuticals, Inc. Cysteine-dependent inverse agonists of nuclear receptors ror-gamma/ror-gamma-t and methods of treating diseases or disorders therewith
WO2020111089A1 (ja) 2018-11-27 2020-06-04 協和キリン株式会社 医薬組成物
CN114126408A (zh) * 2019-05-31 2022-03-01 戴纳立制药公司 嘧啶基氨基-吡唑化合物的改良释放配制品和治疗方法
KR102891865B1 (ko) 2019-07-19 2025-11-26 리아타 파마슈티컬즈, 아이엔씨. C17 극성-치환된 헤테로방향족 합성 트리터페노이드 및 그의 사용 방법
IL298008A (en) 2020-05-09 2023-01-01 Reata Pharmaceuticals Holdings Llc Methods for treating covid-19 with the help of bardoxolone methyl or its analogs
EP4259155A1 (en) 2020-12-11 2023-10-18 Reata Pharmaceuticals Holdings, LLC Synthetic triterpenoids for use in therapy
CN114558019A (zh) * 2022-03-26 2022-05-31 中国科学院昆明动物研究所 一种Rab13基因抑制剂及应用

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6326507B1 (en) 1998-06-19 2001-12-04 Trustees Of Dartmouth College Therapeutic compounds and methods of use
US7435755B2 (en) * 2000-11-28 2008-10-14 The Trustees Of Dartmouth College CDDO-compounds and combination therapies thereof
JP2008110962A (ja) * 2006-08-02 2008-05-15 Santen Pharmaceut Co Ltd Ｎｒｆ２活性化物質を有効成分として含む角結膜障害の予防または治療剤
JP4315182B2 (ja) * 2006-10-30 2009-08-19 ミツミ電機株式会社 カメラモジュール
WO2008111497A1 (ja) * 2007-03-08 2008-09-18 Santen Pharmaceutical Co., Ltd. トリテルペノイドを有効成分として含有する酸化ストレスが関連する眼疾患の予防又は治療剤
US8088824B2 (en) * 2007-08-15 2012-01-03 Reata Pharmaceuticals Inc. Forms of CDDO methyl ester
HUE043175T2 (hu) 2008-01-11 2019-08-28 Reata Pharmaceuticals Inc Szintetikus triterpenoidok és alkalmazásuk betegség kezelésében
PL3254675T3 (pl) 2009-02-13 2019-09-30 Reata Pharmaceuticals, Inc. Kompozycje doustne o opóźnionym uwalnianiu, zawierające amorficzny cddo-me

Also Published As

Publication number Publication date
LT3254675T (lt) 2019-06-25
DK3254675T3 (da) 2019-06-24
ES2646816T3 (es) 2017-12-18
SI3254675T1 (sl) 2019-08-30
HK1220130A1 (zh) 2017-04-28
EP2395979B1 (en) 2017-08-23
US20140235711A1 (en) 2014-08-21
DK2395979T3 (da) 2017-11-27
AU2010213594A1 (en) 2011-08-18
SMT201700527T1 (it) 2018-01-11
HRP20191092T1 (hr) 2019-11-29
PT2395979T (pt) 2017-11-16
BRPI1008023A2 (pt) 2016-03-15
PL2395979T3 (pl) 2018-02-28
HUE044005T2 (hu) 2019-09-30
CA2752048A1 (en) 2010-08-19
AU2010213594B2 (en) 2013-11-14
ES2731601T3 (es) 2019-11-18
CN102387789A (zh) 2012-03-21
IL214258A0 (en) 2011-09-27
US8747901B2 (en) 2014-06-10
MY173715A (en) 2020-02-18
US9155721B2 (en) 2015-10-13
SI2395979T1 (sl) 2017-12-29
CO6361904A2 (es) 2012-01-20
CN105232471A (zh) 2016-01-13
PL3254675T3 (pl) 2019-09-30
KR20140016441A (ko) 2014-02-07
LT2395979T (lt) 2017-12-11
KR20110118721A (ko) 2011-10-31
MX2011008344A (es) 2011-09-29
IL214258A (en) 2017-06-29
WO2010093944A3 (en) 2011-08-11
HRP20171639T1 (hr) 2017-12-15
BRPI1008023B1 (pt) 2019-12-31
CA2752048C (en) 2014-11-25
US20120022156A1 (en) 2012-01-26
CY1122066T1 (el) 2020-11-25
EP3254675B1 (en) 2019-05-15
EP3254675A1 (en) 2017-12-13
ZA201105630B (en) 2012-04-25
EA201190092A1 (ru) 2012-02-28
NO2395979T3 (pt) 2018-01-20
HUE035013T2 (en) 2018-05-02
PT3254675T (pt) 2019-06-14
EA023652B1 (ru) 2016-06-30
NZ594488A (en) 2013-10-25
TR201909743T4 (tr) 2019-07-22
JP2012518008A (ja) 2012-08-09
SG173601A1 (en) 2011-09-29
WO2010093944A2 (en) 2010-08-19
EP2395979A2 (en) 2011-12-21
SMT201900432T1 (it) 2019-09-09
KR101483203B1 (ko) 2015-01-15
CY1119595T1 (el) 2018-03-07
JP5775464B2 (ja) 2015-09-09

Similar Documents

Publication Publication Date Title
CY1122066T1 (el) Χορηγουμενες απο το στομα συνθεσεις καθυστερημενης εκλυσης που περιεχουν αμορφο cddo-me
ES2409069B2 (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
MX2010005346A (es) Composiciones farmaceuticas.
BR112012031500A8 (pt) Composições sólidas
WO2011110854A3 (en) The use of amisulpride as an anti-emetic
BRPI0819936A2 (pt) Preparação farmacêutica, método para produzir células dendríticas, células dendríticas, composição farmacêutica, e, uso de uma célula dendrítica ou uma preparação.
BRPI0814666A2 (pt) composição farmacêutica para a administração oral, uso de uma formulação. processo para a preparação de uma forma de dosagem sólida, e, forma de dosagem sólida
BR112013004016A2 (pt) formulações á base de nalbufina e as respectivas utilizações
BRPI0817503B8 (pt) derivados de purina substituídos por pirimidina, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para a prevenção ou tratamento de uma condição proliferativa
MY160340A (en) Pharmaceutical formulation 514
CL2012002318A1 (es) Compuestos derivados de tieno [2,3-d]pirimidina, inhibidores de quinasa mnk1 y mnk2; composición farmaceutica; que los comprende; y su uso en el tratamiento de enfermedades metabolicas, hematopoyeticas, neurodegenerativas, renales, inflamatorias y cancer.
MX2023008180A (es) Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz.
CR11740A (es) Composiciones que comprenden fármacos levemente básicos y formas de dosificación de liberación controlada
CA2894891A1 (en) Boronic acid derivatives and therapeutic uses thereof
EP2251011A4 (en) SOLID PREPARATION FOR ORAL ADMINISTRATION
BRPI0806863B8 (pt) uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv
ECSP088716A (es) Medicamentos que contienen fluoroquinolonas
TW200800987A (en) Triazolopyridine derivatives as inhibitors of lipases and phospholipases
MX2012013021A (es) Formulaciones resistentes a alcohol.
PT103884A (pt) Composições de libertação prolongada e métodos para a sua preparação
UA103025C2 (ru) Твердая композиция лекарственного средства замедленного высвобождения
MX342181B (es) Formulaciones que comprenden polietilenglicol.
MX2009010483A (es) 5-oxoisoxazoles como inhibidores de lipasas y fosfolipasas.
MX371297B (es) Una composición farmacéutica que comprende nanopartículas híbridas amorfas estables, de al menos un inhibidor de proteína quinasa y al menos un componente estabilizador polimérico y formador de matriz.
EP2497464A3 (en) Pharmaceutical composition of imatinibe methanesulphonate and a process for its manufacture

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06T Formal requirements before examination [chapter 6.20 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 12/02/2010, OBSERVADAS AS CONDICOES LEGAIS.

B25A Requested transfer of rights approved

Owner name: REATA PHARMACEUTICALS HOLDINGS, LLC (US)